



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Ashkenazi, et al. Docket No.: 39780-2730P1C65  
Serial No.: 09/989,727 Group Art Unit: 1647  
Filing Date: November 19, 2001 Examiner: Romeo, David  
For: **SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS  
ENCODING THE SAME**  
Express Mailing Label No.: EL 993 690 075 US  
Mailing Date: December 10, 2004

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

**MS: AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

- ☐ This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):
- ☐ (1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)  
-- OR --
  - ☐ (2) It is being filed within 3 months of entry of a national stage  
-- OR --
  - ☐ (3) It is being filed before the mail date of the first Office Action on the merits  
-- OR --
  - ☐ (4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

☒ 37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:

☐ a certification as specified in §1.97(e) is provided below; **or**

☒ a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.

☐ 37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:

A. a certification as specified in §1.97(e) is completed below; and

B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; **and**

C. a fee of \$180.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.


☒ *Fee Authorization.* The Commissioner is hereby authorized to charge the above-referenced fees of **\$180.00** and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. **08-1641 (Attorney's Docket No. 39780-2730P1C65)**.

Respectfully submitted,

Dated: December 10, 2004

By: Daphne Reddy  
Daphne Reddy, Ph.D. (Reg. No. 53,507)

**HELLER EHRMAN WHITE & MCAULIFFE LLP**  
275 Middlefield Road  
Menlo Park, California 94025-3506  
Telephone: (650) 324-7000  
Facsimile: (650) 324-0638



|   |  |   |                        |                                  |          |                          |                          |
|---|--|---|------------------------|----------------------------------|----------|--------------------------|--------------------------|
| <b>INFORMATION DISCLOSURE STATEMENT</b><br><br>PTO-1449                       |  | <b>ATTY. DOCKET NO.:</b><br>39780-2730P1C65 |                        | <b>SERIAL NO.:</b><br>09/989,727 |          |                          |                          |
|   |  | <b>APPLICANT :</b> Ashkenazi, et al.        |                        |                                  |          |                          |                          |
|   |  | <b>FILING DATE:</b> 11/19/01                |                        | <b>GROUP:</b> 1647               |          |                          |                          |
| <b>U.S. PATENT DOCUMENTS</b>  |  |   |                        |                                  |          |                          |                          |
| EXAMINER'S INITIALS   | PATENT NO.   | DATE  | NAME                   | CLASS                            | SUBCLASS | FILING DATE              |                          |
|   |  |   |                        |                                  |          |                          |                          |
|   |  |   |                        |                                  |          |                          |                          |
| <b>FOREIGN PATENT DOCUMENTS</b>   |  |   |                        |                                  |          |                          |                          |
| EXAMINER'S INITIALS   | PATENT NO.   | DATE  | COUNTRY                | CLASS                            | SUBCLASS | TRANSLATION              |                          |
|   |  |   |                        |                                  |          | YES                      | NO                       |
|   |  |   |                        |                                  |          | <input type="checkbox"/> | <input type="checkbox"/> |
|   |  |   |                        |                                  |          | <input type="checkbox"/> | <input type="checkbox"/> |
| <b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b> |  |   |                        |                                  |          |                          |                          |
|   | Schnabel, M., et al., "Osteoarthritis and Cartilage", Journal of the OsteoArthritis Research Society International, - 10:62-70 (2002).                                       |   |                        |                                  |          |                          |                          |
|   | Zhang, Yaou, et al., "Versican Modulates Embryonic Chondrocyte Morphology via the Epidermal Growth Factor-like Motifs in G3", Experimental Cell Research - 263:33-42 (2001). |   |                        |                                  |          |                          |                          |
|   |  |   |                        |                                  |          |                          |                          |
|   |  |   |                        |                                  |          |                          |                          |
|   |  |   |                        |                                  |          |                          |                          |
|   |  |   |                        |                                  |          |                          |                          |
|   |  |   |                        |                                  |          |                          |                          |
|   |  |   |                        |                                  |          |                          |                          |
|   |  |   |                        |                                  |          |                          |                          |
|   |  |   |                        |                                  |          |                          |                          |
|   |  |   |                        |                                  |          |                          |                          |
|   |  |   |                        |                                  |          |                          |                          |
|   |  |   |                        |                                  |          |                          |                          |
|   |  |   |                        |                                  |          |                          |                          |
|   |  |   |                        |                                  |          |                          |                          |
| <b>EXAMINER</b>   |  |   | <b>DATE CONSIDERED</b> |                                  |          |                          |                          |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.